Richard Heyman - Syndax Pharmaceuticals CoFounder
| 1T3 Stock | EUR 12.80 0.10 0.78% |
Founder
Richard Heyman is CoFounder of Syndax Pharmaceuticals
| Age | 66 |
| Phone | 781 419 1400 |
| Web | https://www.syndax.com |
Richard Heyman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Richard Heyman against Syndax Pharmaceuticals stock is an integral part of due diligence when investing in Syndax Pharmaceuticals. Richard Heyman insider activity provides valuable insight into whether Syndax Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Syndax Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Syndax Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Richard Heyman over three months ago Acquisition by Richard Heyman of 53700 shares of Oric Pharmaceuticals subject to Rule 16b-3 | ||
Richard Heyman over six months ago Acquisition by Richard Heyman of 25600 shares of Oric Pharmaceuticals at 7.9 subject to Rule 16b-3 |
Syndax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.0292) % which means that it has lost $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0519) %, meaning that it generated substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.0519 | |||
| Return On Asset | -0.0292 |
Syndax Pharmaceuticals Leadership Team
Elected by the shareholders, the Syndax Pharmaceuticals' board of directors comprises two types of representatives: Syndax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syndax. The board's role is to monitor Syndax Pharmaceuticals' management team and ensure that shareholders' interests are well served. Syndax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syndax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Briggs MD, Head Pres | ||
| Michael MBA, CEO Director | ||
| Ronald Evans, Advisor CoFounder | ||
| Sharon Klahre, VP Communications | ||
| Peter BSc, CoFounder Officer | ||
| Richard Heyman, CoFounder | ||
| Anjali Ganguli, Chief Officer | ||
| Alexander Nolte, VP Officer | ||
| Keith CPA, Chief Officer | ||
| Michael Downes, CoFounder |
Syndax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syndax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0519 | |||
| Return On Asset | -0.0292 | |||
| Profit Margin | (0.11) % | |||
| Operating Margin | (0.11) % | |||
| Current Valuation | 979.72 M | |||
| Shares Outstanding | 68.1 M | |||
| Shares Owned By Insiders | 4.22 % | |||
| Shares Owned By Institutions | 95.78 % | |||
| Price To Book | 4.08 X | |||
| Price To Sales | 12.70 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Syndax Stock
When determining whether Syndax Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Syndax Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Syndax Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Syndax Pharmaceuticals Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Syndax Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.